183 related articles for article (PubMed ID: 37467017)
1. Ultrasensitive chimerism enhances measurable residual disease testing after allogeneic hematopoietic cell transplantation.
Kanaan SB; Urselli F; Radich JP; Nelson JL
Blood Adv; 2023 Oct; 7(20):6066-6079. PubMed ID: 37467017
[TBL] [Abstract][Full Text] [Related]
2. Post-Transplantation Day +100 Minimal Residual Disease Detection Rather Than Mixed Chimerism Predicts Relapses after Allogeneic Stem Cell Transplantation for Intermediate-Risk Acute Myelogenous Leukemia Patients Undergoing Transplantation in Complete Remission.
Klyuchnikov E; Badbaran A; Massoud R; Fritzsche-Friedland U; Freiberger P; Ayuk F; Wolschke C; Bacher U; Kröger N
Transplant Cell Ther; 2022 Jul; 28(7):374.e1-374.e9. PubMed ID: 35429661
[TBL] [Abstract][Full Text] [Related]
3. Post-transplant cyclophosphamide and early mixed donor Chimerism in myeloid malignancies; a single-center experience.
Hoff FW; Chung SS; Patel PA; Premnath N; Khatib J; Tadic-Ovcina M; AhmedRabie A; Helton D; Yohannes S; Shahan J; Patel H; Geethakumari PR; Vusirikala M; Collins RH; Madanat YF
Transpl Immunol; 2023 Apr; 77():101808. PubMed ID: 36842566
[TBL] [Abstract][Full Text] [Related]
4. Multigene Measurable Residual Disease Assessment Improves Acute Myeloid Leukemia Relapse Risk Stratification in Autologous Hematopoietic Cell Transplantation.
Mulé MP; Mannis GN; Wood BL; Radich JP; Hwang J; Ramos NR; Andreadis C; Damon L; Logan AC; Martin TG; Hourigan CS
Biol Blood Marrow Transplant; 2016 Nov; 22(11):1974-1982. PubMed ID: 27544285
[TBL] [Abstract][Full Text] [Related]
5. The mythological chimera and new era of relapse prediction post-transplant.
Ciurea SO; Kothari A; Sana S; Al Malki MM
Blood Rev; 2023 Jan; 57():100997. PubMed ID: 35961800
[TBL] [Abstract][Full Text] [Related]
6. Minimal residual disease after allogeneic stem cell transplant: a comparison among multiparametric flow cytometry, Wilms tumor 1 expression and chimerism status (Complete chimerism versus Low Level Mixed Chimerism) in acute leukemia.
Rossi G; Carella AM; Minervini MM; Savino L; Fontana A; Pellegrini F; Greco MM; Merla E; Quarta G; Loseto G; Capalbo S; Palumbo G; Cascavilla N
Leuk Lymphoma; 2013 Dec; 54(12):2660-6. PubMed ID: 23547840
[TBL] [Abstract][Full Text] [Related]
7. [Prognostic value of donor chimerism at +90 days after allogeneic hematopoietic stem cell transplantation in young patients with intermediate-risk acute myeloid leukemia].
Fei Y; Hu XX; Chen Q; Huang AJ; Cheng H; Ni X; Qiu HY; Gao L; Tang GS; Chen J; Zhang WP; Yang JM; Wang JM
Zhonghua Xue Ye Xue Za Zhi; 2019 Dec; 40(12):990-995. PubMed ID: 32023728
[No Abstract] [Full Text] [Related]
8. Chimerism and minimal residual disease monitoring after reduced intensity conditioning (RIC) allogeneic transplantation.
Pérez-Simón JA; Caballero D; Diez-Campelo M; Lopez-Pérez R; Mateos G; Cañizo C; Vazquez L; Vidriales B; Mateos MV; Gonzalez M; San Miguel JF
Leukemia; 2002 Aug; 16(8):1423-31. PubMed ID: 12145680
[TBL] [Abstract][Full Text] [Related]
9. WT1 Measurable Residual Disease Assay in Patients With Acute Myeloid Leukemia Who Underwent Allogeneic Hematopoietic Stem Cell Transplantation: Optimal Time Points, Thresholds, and Candidates.
Cho BS; Min GJ; Park SS; Shin SH; Yahng SA; Jeon YW; Yoon JH; Lee SE; Eom KS; Kim YJ; Lee S; Min CK; Cho SG; Kim DW; Lee JW; Kim M; Kim Y; Kim HJ
Biol Blood Marrow Transplant; 2019 Oct; 25(10):1925-1932. PubMed ID: 31173897
[TBL] [Abstract][Full Text] [Related]
10. Chimerism Testing by Next Generation Sequencing for Detection of Engraftment and Early Disease Relapse in Allogeneic Hematopoietic Cell Transplantation and an Overview of NGS Chimerism Studies.
Liacini A; Tripathi G; McCollick A; Gravante C; Abdelmessieh P; Shestovska Y; Mathew L; Geier S
Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511573
[TBL] [Abstract][Full Text] [Related]
11. Comparison of chimerism and minimal residual disease monitoring for relapse prediction after allogeneic stem cell transplantation for adult acute lymphoblastic leukemia.
Terwey TH; Hemmati PG; Nagy M; Pfeifer H; Gökbuget N; Brüggemann M; Le Duc TM; le Coutre P; Dörken B; Arnold R
Biol Blood Marrow Transplant; 2014 Oct; 20(10):1522-9. PubMed ID: 24907626
[TBL] [Abstract][Full Text] [Related]
12. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
13. Pre- and post-transplant quantification of measurable ('minimal') residual disease via multiparameter flow cytometry in adult acute myeloid leukemia.
Zhou Y; Othus M; Araki D; Wood BL; Radich JP; Halpern AB; Mielcarek M; Estey EH; Appelbaum FR; Walter RB
Leukemia; 2016 Jul; 30(7):1456-64. PubMed ID: 27012865
[TBL] [Abstract][Full Text] [Related]
14. Droplet digital PCR for the simultaneous analysis of minimal residual disease and hematopoietic chimerism after allogeneic cell transplantation.
Waterhouse M; Pfeifer D; Duque-Afonso J; Follo M; Duyster J; Depner M; Bertz H; Finke J
Clin Chem Lab Med; 2019 Apr; 57(5):641-647. PubMed ID: 30457973
[TBL] [Abstract][Full Text] [Related]
15. Quantitative chimerism kinetics in relapsed leukemia patients after allogeneic hematopoietic stem cell transplantation.
Qin XY; Li GX; Qin YZ; Wang Y; Wang FR; Liu DH; Xu LP; Chen H; Han W; Wang JZ; Zhang XH; Li JL; Li LD; Liu KY; Huang XJ
Chin Med J (Engl); 2012 Jun; 125(11):1952-9. PubMed ID: 22884060
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of minimal residual disease by real-time quantitative PCR of Wilms' tumor 1 expression in patients with acute myelogenous leukemia after allogeneic stem cell transplantation: correlation with flow cytometry and chimerism.
Kwon M; Martínez-Laperche C; Infante M; Carretero F; Balsalobre P; Serrano D; Gayoso J; Pérez-Corral A; Anguita J; Díez-Martín JL; Buño I
Biol Blood Marrow Transplant; 2012 Aug; 18(8):1235-42. PubMed ID: 22281301
[TBL] [Abstract][Full Text] [Related]
17. Peripheral Blood CD34 Donor Chimerism has Greater Clinical Utility Than CD3 for Detecting Relapse after Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia or Myelodysplastic Syndrome.
Das TP; North D; Fleming SA; Tan JLC; Ivey A; Cummings NJ; Spencer A; Patil SS; Widjaja JML; Swain MI; Bourke C; O'Brien ME; Kliman DS; Curtis DJ
Transplant Cell Ther; 2023 Jul; 29(7):454.e1-454.e8. PubMed ID: 36966870
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of a Second Allogeneic Hematopoietic Cell Transplant in Relapsed Acute Myeloid Leukemia: Results of a Systematic Review and Meta-Analysis.
Kharfan-Dabaja MA; Reljic T; Yassine F; Nishihori T; Kumar A; Tawk MM; Keller K; Ayala E; Savani B; Mohty M; Aljurf M; Saber W
Transplant Cell Ther; 2022 Nov; 28(11):767.e1-767.e11. PubMed ID: 35970301
[TBL] [Abstract][Full Text] [Related]
19. Chimerism evaluation in measurable residual disease-suspected cells isolated by flow cell sorting as a reliable tool for measurable residual disease verification in acute leukemia patients after allogeneic hematopoietic stem cell transplantation.
Semchenkova A; Brilliantova V; Shelikhova L; Zhogov V; Illarionova O; Mikhailova E; Raykina E; Skorobogatova E; Novichkova G; Maschan A; Maschan M; Popov A
Cytometry B Clin Cytom; 2021 Sep; 100(5):568-573. PubMed ID: 33369016
[TBL] [Abstract][Full Text] [Related]
20. Assessment of chimerism by next generation sequencing: A comparison to STR/qPCR methods.
Brow D; Shike H; Kendrick J; Pettersson L; Mineishi S; Claxton DF; Wirk B; Cioccio J; Greiner RJ; Viswanatha D; Kharfan-Dabaja MA; Li Z; Tyler J; Elrefaei M
Hum Immunol; 2024 May; 85(3):110794. PubMed ID: 38553384
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
